Skip to main content

Call for papers

Advances in Nanomedicine for Cancer Therapy

Molecular Cancer invites submissions to this article collection. This Collection aims to explore innovative research and breakthrough developments in the application of nanotechnology for cancer diagnosis, treatment, and management. The collection is open to submissions till 31 December 2024.

Aging and Cellular Fate: Senescence, Death, or Cancer

Molecular Cancer invites submissions to this article collection. This Collection aims to unravel complex interplay between cellular aging processes, such as senescence and apoptosis, and their impact on cancer initiation, progression, and therapeutic responses. The collection is open to submissions till 31 October 2024.

Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance

Molecular Cancer is calling for submissions to our Collection on 'Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance.' We welcome Reviews and Correspondences that address this multifaceted role of biomarkers in guiding personalized treatment strategies, improving patient outcomes, and advancing our understanding of cancer biology. Original Articles are not accepted. The collection is open to submissions till 31st July 2024.

Molecular understanding and clinical aspects of immunotherapy in the treatment of cancer

Molecular Cancer invites submissions to this article collection. Topics of interest include, but are not limited to, adoptive cellular immunotherapy, chimeric antigen receptor T-cell (CAR-T) immunotherapy, immune checkpoint inhibitors, modulators of tumor microenvironment, and drug resistance mechanisms in immunotherapy. The collection is open to submissions from August 15th 2022 to September 15th 2023.

Special Issues

Phase 2 and 3 studies

Molecular Cancer presents its new Article Collection on "Phase 2 and 3 studies".

Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments

This special issue published by Molecular Cancer focuses on the clinical aspects of liquid biopsies, in particular validation of novel biomarkers that may serve as signature for non-invasive early detection of cancerous cells, predict patients' risks of disease progression and response to specific therapies.

Genome Editing and the Future of Personalized and Targeted Cancer Medicine

Molecular Cancer is excited to present a series of original research and review articles related to genome editing and reprogramming.


Christophe Nicot, Kansas University Medical Center, USA

Aims and scope

Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.

Read more


  1. Authors: Andriani Angelopoulou, Giorgos Theocharous, Dimitrios Valakos, Aikaterini Polyzou, Sophia Magkouta, Vassilios Myrianthopoulos, Sophia Havaki, Marco Fiorillo, Ioanna Tremi, Konstantinos Vachlas, Theodoros Nisotakis, Dimitris-Foivos Thanos, Anastasia Pantazaki, Dimitris Kletsas, Jiri Bartek, Russell Petty…

Colorectal Cancer Awareness Month

In recognition of Colorectal Cancer Awareness Month this March, we have selected a collection of articles on colorectal cancer from across our open access portfolio. Together, these articles contribute to the evolving landscape of colorectal cancer research and the fight against this prevalent and impactful disease.
© Mopic /

2021 Thematic Series: mRNA therapies and mRNA vaccines in cancer

2021 SI imageMolecular Cancer is delighted to announce its new thematic series: mRNA therapies and mRNA vaccines in cancer

Click here to access all thematic series published to date in Molecular Cancer.

Featured Article: Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy

New Content ItemThe CRISPR system is a revolutionary genome editing tool that has the potential to revolutionize the field of cancer research and therapy. The ability to precisely target and edit specific genetic mutations that drive the growth and spread of tumors has opened up new possibilities for the development of more effective and personalized cancer treatments.

In this review, the authors will discuss the different CRISPR-based strategies that have been proposed for cancer therapy, including inactivating genes that drive tumor growth, enhancing the immune response to cancer cells, repairing genetic mutations that cause cancer, and delivering cancer-killing molecules directly to tumor cells.

CAHON: Stop hate crimes and racism

The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. Molecular Cancer is proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.

Recognising Editorial Excellence

Editorial Excellence BadgeMolecular Cancer is a top rated Springer Nature journal. Prof. Christophe Nicot and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

What is trending?

Altmetric doughnutClick here to see which articles published in Microbiome have been shared the most in 2021.

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 27.7
    5-year Journal Impact Factor: 31.3
    Source Normalized Impact per Paper (SNIP): 4.737
    SCImago Journal Rank (SJR): 8.222

    Speed 2023
    Submission to first editorial decision (median days): 3
    Submission to acceptance (median days): 91

    Usage 2023
    Downloads: 3,569,666
    Altmetric mentions: 2,070